CE
Cerus Corporation
CERS · NASDAQ
$2.65 +0.19% (+$0.01)
1M -1.49%
Market Cap $534.0M
P/E Ratio -
Div. Yield -
ROE 10.31%
Bulios Fair Price
$1.44
45.7% downside
Current Price
$2.65
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CERS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
16 /100
Expensive P/S 2.41x
P/B 7.63x
EV/EBITDA 203.87x
Growth
50 /100
Stable Book val. growth 1.70%
Rev. growth 8.35%
FCF growth N/A
Profitability
20 /100
Weak Net margin 3.06%
Op. margin 0.73%
FCF margin 0.83%
Quality
14 /100
Poor ROE 10.31%
ROA 3.31%
Asset turnover 1.08x
Debt
28 /100
High Current ratio 1.83x
Int. coverage 0.16x
Net debt/EBITDA 20.23x
Stability
58 /100
Moderate Rev. volatility 10.59%
EPS volatility 17.76%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CERS
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Vivek K. Jayaraman
Employees
268
Headquarters
Concord
Upcoming events
05 NOV
Earnings
Upcoming earnings report